Company intelligence
Delve Bio
Providing Molecular Insights for the Precision Care of the Sickest Patients
Biotechnology Research
Boston, US
43 employees
Founded 2022
3 public signals
About Delve Bio
We are a well-funded biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.
Verified activity
Signals from Delve Bio
3 published signals
Research & Knowledge
Delve Bio published a newly published case study showing how CSF mNGS provided clarity during a prolonged diagnostic journey for an immunocompromised adolescent with chronic meningoencephalitis.
Reported by Delve Bio
Research & Knowledge
Delve Bio published findings in Nature Medicine showing mNGS achieved 63.1% sensitivity outperforming standard CSF direct detection methods like cultures and PCR.
Reported by Delve Bio
Research & Knowledge
Delve Bio published findings in the Nature Medicine publication showing that Delve Detect outperformed conventional diagnostic testing methods for CNS infections.
Reported by Jeffrey Field, M.S., MBA